Version 1
: Received: 11 October 2022 / Approved: 13 October 2022 / Online: 13 October 2022 (11:52:50 CEST)
How to cite:
Thomsen, M.S.; Johnsen, K.B.; Kucharz, K.; Lauritzen, M.; Moos, T. Blood-Brain Barrier Transport of Transferrin-Receptor Targeted Nanoparticles. Preprints2022, 2022100194. https://doi.org/10.20944/preprints202210.0194.v1
Thomsen, M.S.; Johnsen, K.B.; Kucharz, K.; Lauritzen, M.; Moos, T. Blood-Brain Barrier Transport of Transferrin-Receptor Targeted Nanoparticles. Preprints 2022, 2022100194. https://doi.org/10.20944/preprints202210.0194.v1
Thomsen, M.S.; Johnsen, K.B.; Kucharz, K.; Lauritzen, M.; Moos, T. Blood-Brain Barrier Transport of Transferrin-Receptor Targeted Nanoparticles. Preprints2022, 2022100194. https://doi.org/10.20944/preprints202210.0194.v1
APA Style
Thomsen, M.S., Johnsen, K.B., Kucharz, K., Lauritzen, M., & Moos, T. (2022). Blood-Brain Barrier Transport of Transferrin-Receptor Targeted Nanoparticles. Preprints. https://doi.org/10.20944/preprints202210.0194.v1
Chicago/Turabian Style
Thomsen, M.S., Martin Lauritzen and Torben Moos. 2022 "Blood-Brain Barrier Transport of Transferrin-Receptor Targeted Nanoparticles" Preprints. https://doi.org/10.20944/preprints202210.0194.v1
Abstract
The blood-brain barrier (BBB), built by brain endothelial cells (BECs), is impermeable to biologics. Liposomes and other nanoparticles are good candidates for delivery of biologics across the BECs, as they can encapsulate numerous molecules of interest in an omnipotent manner. The liposomes need attachment of a targeting molecule, as BECs unfortunately are virtually incapable of uptake of non-targeted liposomes from the circulation. Experiments of independent research groups have qualified antibodies targeting the transferrin receptor as superior for targeted delivery of nanoparticles to BECs. Functionalization of nanoparticles via conjugation with anti-transferrin receptor antibodies leads to nanoparticle uptake by endothelial cells of both brain capillaries and post-capillary venules. Reducing the density of transferrin receptor-targeted antibodies conjugated to liposomes limits uptake in BECs. Opposing the transport of nanoparticles conjugated to high-affine anti-transferrin receptor antibodies, lowering the affinity of the targeting antibodies or implementing monovalent antibodies increase uptake by BECs and allows for further transport across the BBB. The novel demonstration of transport of targeted liposomes in post-capillary venules from blood to the brain is interesting and clearly warrants further mechanistic pursuit. The recent evidence for passing targeted nanoparticles through the BBB shows great promise for future drug delivery of biologics to the brain.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
